New York location for dermatology study by Equity Medical
Study Location
New York

Overview

Recruiting start date
  • January 15, 2025
Duration
  • 24 weeks
Population

2 Years to 11 Years (Child ) with NonSegmental Vitiligo

Study Drug

Ruxolitinib Cream

Inclusion Criteria
  • Clinical diagnosis of nonsegmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, ≥ 3 T-VASI.
  • Total body vitiligo area does not exceed 10% BSA.
  • Pigmented hair within some of the areas of vitiligo on the face.
  • Must agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit.
Exclusion Criteria
  • Diagnosis of other forms of vitiligo (eg, segmental).
  • Other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).
  • Any other skin disease that, in the opinion of the investigator, would interfere with the study drug application or study assessments.
  • Prior or current use of depigmentation treatments (eg, monobenzone).
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator’s opinion, would interfere with full participation in the study, including application of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Use of protocol-defined treatments within the indicated washout period before baseline.
  • Current or previous use of JAK inhibitors, systemic or topical.
  • Protocol-defined clinically significant abnormal laboratory values at screening.
  • BMI-for-age < 5th percentile or ≥ 85th percentile according to the CDC BMI Percentile Calculator for Child and Teen.
  • In the opinion of the investigator, unable or unlikely to comply with the application schedule and study evaluations.
  • Living with anyone participating in any current Incyte-sponsored ruxolitinib cream study.
  • Employees of the sponsor or investigator or are otherwise dependents of them.
  • Known allergy or reaction to any component of the study cream formulation.
What You Can Expect

The study will include visits to our study center where the patient will initially receive a thorough physical examination, including an EKG and blood work at no cost to the patient to assess the participant’s baseline health. Moreover, the patient will receive a screening examination from a dermatology specialist to confirm the diagnosis of the study disease. After informed consent and if the participant elects to continue in the study, the patient will either be given the active medication (i.e. Ruxolitinib ) or a placebo. There will be regular follow-up visits to assess the effectiveness and safety of the therapies.

Contact us to join a dermatology study clinical trial

Contact Us Today!

Whether it be eczema, dandruff, or psoriasis, being a part of our research is an impactful way to explore treatments and medications. Even if there isn’t a current study that’s a perfect fit for you, take the first step and sign up to learn more and be considered for future studies in New York and Kentucky. Click the button below to get started!